Shortly after scoring an FDA approval for its Amplatzer Amulet structural heart device this month, Abbott delivered late-breaking clinical trial data putting it up against its main competitor, Boston ...

ABBOTT PARK, Ill., Aug. 30, 2021 /PRNewswire/ -- Abbott (NYSE: ABT) today announced late-breaking data from the Amulet™ LAA Occluder IDE trial, a multi-center, head-to-head study comparing the company ...

First and only steerable delivery system designed to help seal the left atrial appendage (LAA) in people with atrial fibrillation who are at an increased risk of stroke Now available in the U.S., ...

Abbott Laboratories ABT recently received the FDA go-ahead for its Amplatzer Amulet Left Atrial Appendage Occluder to treat people with atrial fibrillation (AFib) who are at risk of ischemic stroke.

Abbott Laboratories ABT recently presented late-breaking data from the Amulet LAA Occluder IDE trial comparing the company's Amplatzer Amulet Left Atrial Appendage (LAA) Occluder with Boston ...

Abbott Laboratories ABT recently presented late-breaking data from the Amulet LAA Occluder IDE trial comparing the company's Amplatzer Amulet Left Atrial Appendage (LAA) Occluder with Boston ...

ABBOTT PARK, Ill., April 28, 2022 /PRNewswire/ -- Abbott (NYSE: ABT) today announced U.S. availability of its Amplatzer™ Steerable Delivery Sheath, which is used with the company's Amplatzer Amulet™ ...

Abbott has received a new, broad approval from the FDA for its tiny heart plug implant to help cut down the risk of stroke among people with atrial fibrillation, the most common cardiac arrhythmia.

Abbott announced late-breaking data from the Amulet LAA Occluder IDE trial, a multi-center, head-to-head study comparing the company's Amplatzer Amulet Left Atrial Appendage (LAA) Occluder with the ...

Abbott Laboratories ABT recently received the FDA go-ahead for its Amplatzer Amulet Left Atrial Appendage Occluder to treat people with atrial fibrillation (AFib) who are at risk of ischemic stroke.

The race is on. After six years as the only FDA approved devices for left atrial appendage closure, Boston Scientific Corp.’s Watchman products face a challenger, Abbott Laboratories’ Amplatzer Amulet ...

The U.S. FDA has given its nod for a new trial of Abbott Laboratories’ Amplatzer Amulet left atrial appendage (LAA) occluder for those with atrial fibrillation (AF) who are at risk of stroke. Known as ...